B. Riley Financial Cuts Altimmune (NASDAQ:ALT) Price Target to $13.00

Altimmune (NASDAQ:ALT) had its target price cut by B. Riley Financial from $18.00 to $13.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also recently issued reports on the stock. Barclays began coverage on shares of Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Citigroup reissued a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. William Blair restated a “market perform” rating on shares of Altimmune in a research report on Thursday. Finally, Citizens Jmp lowered their price objective on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $16.60.

Altimmune Stock Up 0.9%

Shares of NASDAQ:ALT opened at $3.54 on Friday. The company’s fifty day moving average is $4.48 and its two-hundred day moving average is $4.29. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18. Altimmune has a 1-year low of $2.90 and a 1-year high of $7.73. The stock has a market capitalization of $399.43 million, a price-to-earnings ratio of -3.50 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 54.03%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.00 million. Equities analysts anticipate that Altimmune will post -1.35 EPS for the current year.

Insider Transactions at Altimmune

In other news, Director John Gill purchased 12,500 shares of the company’s stock in a transaction on Tuesday, December 23rd. The shares were bought at an average price of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the purchase, the director owned 12,500 shares of the company’s stock, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerome Benedict Durso purchased 12,500 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the acquisition, the director owned 12,500 shares of the company’s stock, valued at approximately $51,625. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 30,527 shares of company stock valued at $125,278 over the last three months. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Altimmune

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. increased its position in Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after acquiring an additional 1,928 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares in the last quarter. Concurrent Investment Advisors LLC boosted its position in Altimmune by 10.4% during the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock worth $96,000 after acquiring an additional 2,500 shares during the period. The Manufacturers Life Insurance Company boosted its position in Altimmune by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock worth $108,000 after acquiring an additional 2,748 shares during the period. Finally, Deutsche Bank AG grew its stake in shares of Altimmune by 4.0% in the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock worth $289,000 after purchasing an additional 3,047 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

Key Stories Impacting Altimmune

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Company advanced pemvidutide development — management reiterated plans to initiate a Phase 3 MASH trial in 2026, pemvidutide received FDA Breakthrough Therapy designation for MASH, and RECLAIM Phase 2 topline data in AUD is expected in 3Q 2026. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Balance sheet strengthened — company reported about $274M in cash, cash equivalents and short-term investments at year-end and completed a $75M registered direct offering in January, supporting clinical programs and runway. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Company outlined a large, 1,800‑patient Phase III MASH design and signaled cash runway into 2028 as pemvidutide advances — this reduces near-term execution risk for the lead program. Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028
• Neutral Sentiment: B. Riley cut its price target from $18 to $13 but kept a Buy rating — the new target still implies meaningful upside vs. current levels, though it reduces analyst enthusiasm relative to prior coverage. Benzinga
• Neutral Sentiment: Earnings call and transcripts are available for review — useful for investors who want management’s commentary on timelines, trial designs and cash runway. Altimmune Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short-interest notes appear to show anomalous/zero values in public data feeds and are not a reliable signal at this time.
• Negative Sentiment: Q4 earnings missed estimates — EPS of ($0.27) vs. consensus ($0.25) and immaterial GAAP revenue ($0.03M); very large negative margins and negative ROE highlight ongoing R&D spending and lack of commercial revenue. Altimmune stock edges down on fourth quarter earnings miss

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.